Full Text View
Tabular View
No Study Results Posted
Related Studies
GSK1120212 Rollover Study
This study is currently recruiting participants.
Verified April 2013 by GlaxoSmithKline
Study NCT01376310   Information provided by GlaxoSmithKline

First Received on February 3, 2011.   Last Updated on April 18, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cancer
Interventions listed in this trial
GSK1120212
Docetaxel + GSK1120212
Erlotinib + GSK1120212
Pemetrexed + GSK1120212
Carboplatin + GSK1120212
Nab-paclitaxel + GSK1120212
Gemcitabine + GSK1120212
Everolimus + GSK1120212
Additional drug interventions recognized in this trial
Carboplatin
Docetaxel
Erlotinib
Everolimus
Gemcitabine
Paclitaxel
Pemetrexed
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiviral Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Radiation-Sensitizing Agents
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services